Quirós LP, Ugalde R. Analysis of the budgetary impact of alemtuzumab as second-line therapy, compared to natalizumab and fingolimod, in patients previously treated with interferon beta 1b, diagnosed with active relapsing-remitting multiple sclerosis, treated in the Costa Rican social security fund. Grhta [Internet]. 2019 Mar. 8 [cited 2024 Nov. 24];6(1). Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/467